See the published version of this preprint at Lipids in Health and Disease.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research
Elham Chamani
Birjand University of Medical Sciences
Corresponding Author
ORCiD: https://orcid.org/0000-0002-4615-0034
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background
Meteorin-like (Metrnl) is a newly discovered adipokine with the anti-inflammatory and insulin sensitizing properties. Accordingly, Metrnl regulates glucose tolerance, enhances metabolism in body tissues, and induces thermogenesis in white adipose tissue. However, the correlation among Metrnl, IBD, and obesity still remains unexplored.
Methods
The present study was conducted on 54 healthy control, 42 Ulcerative Colitis (UC), and 43 Crohn's disease (CD) patients who were diagnosed by pathological examination. In these patients, serum levels of adiponectin, Metrnl, IL-6, and TNF-α were measured using ELISA kits.
Results
Metrnl concentration significantly decreased in both of the UC (85.25 ± 36.55 pg/mL) and CD (76.93 ± 27.92 pg/mL) patients compared to control group (107.52 ± 35.33 pg/mL). Similarly, adiponectin has also decreased in these two patient groups compared to the controls. However, IL-6 and TNF-α significantly increased in both of the patient groups. Moreover, Metrnl indicated an inverse relationship with BMI in the controls and both of the patient groups. In addition, there was an inverse correlation among Metrnl, IL-6, and TNF-α in both of the patient groups.
Conclusions
The current study is the first one reporting the decreased Metrnl serum level in the patients with IBD, which is inversely related to BMI, TNF-α, and IL-6. These results suggested a possible role for Metrnl in the pathogenesis of IBD, particularly through inflammation modulating.
Keywords
Metrnl, IBD, Ulcerative Colitis, Crohn's disease
Figure 1
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Lipids in Health and Disease.
No community comments so far
Editorial decision: Accept
On 19 Oct, 2020
Review #1 received
Received 18 Oct, 2020
Reviewers invited
Invitations sent on 16 Oct, 2020
Reviewer #1 agreed
On 16 Oct, 2020
Editor assigned
On 15 Oct, 2020
Submission checks complete
On 14 Oct, 2020
Editor invited
On 14 Oct, 2020
No comments provided
Editorial decision: Major revision
On 08 Oct, 2020
Review #4 received
Received 06 Oct, 2020
Review #2 received
Received 04 Oct, 2020
Reviewer #4 agreed
On 03 Oct, 2020
Reviewer #3 agreed
On 29 Sep, 2020
Review #1 received
Received 29 Sep, 2020
Review #3 received
Received 29 Sep, 2020
Editor assigned
On 28 Sep, 2020
Reviewers invited
Invitations sent on 28 Sep, 2020
Reviewer #1 agreed
On 28 Sep, 2020
Reviewer #2 agreed
On 28 Sep, 2020
Submission checks complete
On 27 Sep, 2020
Editor invited
On 27 Sep, 2020
No comments provided
Editorial decision: Major revision
On 19 Sep, 2020
Review #4 received
Received 18 Sep, 2020
Review #3 received
Received 14 Sep, 2020
Reviewer #4 agreed
On 10 Sep, 2020
Reviewer #3 agreed
On 10 Sep, 2020
Review #2 received
Received 02 Sep, 2020
Editor assigned
On 01 Sep, 2020
Reviewers invited
Invitations sent on 01 Sep, 2020
Reviewer #1 agreed
On 01 Sep, 2020
Reviewer #2 agreed
On 01 Sep, 2020
Review #1 received
Received 01 Sep, 2020
Submission checks complete
On 31 Aug, 2020
Editor invited
On 31 Aug, 2020
Version 1
Posted 06 Jul, 2020
No comments provided
Review #2 received
Received 21 Jul, 2020
Editorial decision: Major revision
On 21 Jul, 2020
Review #1 received
Received 18 Jul, 2020
Review #3 received
Received 12 Jul, 2020
Review #4 received
Received 12 Jul, 2020
Reviewer #4 agreed
On 09 Jul, 2020
Reviewer #3 agreed
On 07 Jul, 2020
Reviewer #2 agreed
On 05 Jul, 2020
Reviewer #1 agreed
On 04 Jul, 2020
Editor assigned
On 03 Jul, 2020
Reviewers invited
Invitations sent on 03 Jul, 2020
First submitted
On 02 Jul, 2020
Submission checks complete
On 02 Jul, 2020
Editor invited
On 02 Jul, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
See the published version of this preprint at Lipids in Health and Disease.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Elham Chamani
Birjand University of Medical Sciences
Corresponding Author
ORCiD: https://orcid.org/0000-0002-4615-0034
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Lipids in Health and Disease.
No community comments so far
Editorial decision: Accept
On 19 Oct, 2020
Review #1 received
Received 18 Oct, 2020
Reviewers invited
Invitations sent on 16 Oct, 2020
Reviewer #1 agreed
On 16 Oct, 2020
Editor assigned
On 15 Oct, 2020
Submission checks complete
On 14 Oct, 2020
Editor invited
On 14 Oct, 2020
No comments provided
Editorial decision: Major revision
On 08 Oct, 2020
Review #4 received
Received 06 Oct, 2020
Review #2 received
Received 04 Oct, 2020
Reviewer #4 agreed
On 03 Oct, 2020
Reviewer #3 agreed
On 29 Sep, 2020
Review #1 received
Received 29 Sep, 2020
Review #3 received
Received 29 Sep, 2020
Editor assigned
On 28 Sep, 2020
Reviewers invited
Invitations sent on 28 Sep, 2020
Reviewer #1 agreed
On 28 Sep, 2020
Reviewer #2 agreed
On 28 Sep, 2020
Submission checks complete
On 27 Sep, 2020
Editor invited
On 27 Sep, 2020
No comments provided
Editorial decision: Major revision
On 19 Sep, 2020
Review #4 received
Received 18 Sep, 2020
Review #3 received
Received 14 Sep, 2020
Reviewer #4 agreed
On 10 Sep, 2020
Reviewer #3 agreed
On 10 Sep, 2020
Review #2 received
Received 02 Sep, 2020
Editor assigned
On 01 Sep, 2020
Reviewers invited
Invitations sent on 01 Sep, 2020
Reviewer #1 agreed
On 01 Sep, 2020
Reviewer #2 agreed
On 01 Sep, 2020
Review #1 received
Received 01 Sep, 2020
Submission checks complete
On 31 Aug, 2020
Editor invited
On 31 Aug, 2020
Version 1
Posted 06 Jul, 2020
No comments provided
Review #2 received
Received 21 Jul, 2020
Editorial decision: Major revision
On 21 Jul, 2020
Review #1 received
Received 18 Jul, 2020
Review #3 received
Received 12 Jul, 2020
Review #4 received
Received 12 Jul, 2020
Reviewer #4 agreed
On 09 Jul, 2020
Reviewer #3 agreed
On 07 Jul, 2020
Reviewer #2 agreed
On 05 Jul, 2020
Reviewer #1 agreed
On 04 Jul, 2020
Editor assigned
On 03 Jul, 2020
Reviewers invited
Invitations sent on 03 Jul, 2020
First submitted
On 02 Jul, 2020
Submission checks complete
On 02 Jul, 2020
Editor invited
On 02 Jul, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at Lipids in Health and Disease.
Background
Meteorin-like (Metrnl) is a newly discovered adipokine with the anti-inflammatory and insulin sensitizing properties. Accordingly, Metrnl regulates glucose tolerance, enhances metabolism in body tissues, and induces thermogenesis in white adipose tissue. However, the correlation among Metrnl, IBD, and obesity still remains unexplored.
Methods
The present study was conducted on 54 healthy control, 42 Ulcerative Colitis (UC), and 43 Crohn's disease (CD) patients who were diagnosed by pathological examination. In these patients, serum levels of adiponectin, Metrnl, IL-6, and TNF-α were measured using ELISA kits.
Results
Metrnl concentration significantly decreased in both of the UC (85.25 ± 36.55 pg/mL) and CD (76.93 ± 27.92 pg/mL) patients compared to control group (107.52 ± 35.33 pg/mL). Similarly, adiponectin has also decreased in these two patient groups compared to the controls. However, IL-6 and TNF-α significantly increased in both of the patient groups. Moreover, Metrnl indicated an inverse relationship with BMI in the controls and both of the patient groups. In addition, there was an inverse correlation among Metrnl, IL-6, and TNF-α in both of the patient groups.
Conclusions
The current study is the first one reporting the decreased Metrnl serum level in the patients with IBD, which is inversely related to BMI, TNF-α, and IL-6. These results suggested a possible role for Metrnl in the pathogenesis of IBD, particularly through inflammation modulating.
Figure 1
Loading...